Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 3Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Leukemia 1Inflammatory Breast Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Disease Progression 1Disease 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1

Interventions

pembrolizumab 43Nivolumab 24Gemcitabine 23Cyclophosphamide 21Paclitaxel 17Capecitabine 16fludarabine 14Ipilimumab 14aldesleukin 11Docetaxel 11130-nm albumin-bound paclitaxel 11Trastuzumab 10Cetuximab 10Bevacizumab 10Albumin-Bound Paclitaxel 9fludarabine phosphate 8Specimen Handling 8Interleukin-2 8Fluorouracil 8Cisplatin 8Biopsy 8Radiosurgery 7Oxaliplatin 7Irinotecan 7durvalumab 6avelumab 6Temozolomide 6Pemetrexed 6Leucovorin 6Carboplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm Metastasis × neratinib × Clear all
NCT00741260 2018-09-05

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Puma Biotechnology, Inc.

Phase 1/2 Completed
105 enrolled 19 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡